期刊文献+

血清HE4、CA125联合检测对卵巢癌的诊断价值 被引量:5

Diagnostic value of combined detection of serum HE4 and CA125 in ovarian cancer
下载PDF
导出
摘要 目的研究肿瘤标记物血清人附睾分泌蛋白4(HE4)与糖类抗原125(CA125)联合检测对卵巢癌的诊断价值。方法选择2013年7月-2015年7月在我院就诊的100例卵巢癌患者为观察组,100例体检健康者为对照组,采用酶联免疫法(ELISA)检测100例不同分期卵巢癌患者及100例健康对照组患者的血清HE4水平,采用化学发光免疫定量分析法(ECLIA)检测CA125水平,检测数据进行统计学分析,探究两标志物单项或联合检测对卵巢癌的诊断价值。结果观察组与对照组相比血清HE4与CA125水平明显升高,差异有统计学意义(P〈0.05),血清HE4与CA125联合检测的诊断结果显示其敏感性、特异性及准确性分别为88%、93%和91%,均高于血清HE4(81%、81%、82%)与CA125(73%、83%、83%)的单项检测。结论血清HE4与CA125联合检测对卵巢癌的诊断有重要意义,可以提高卵巢癌的诊断效能,对卵巢癌的早鉴别、早诊断、早治疗具有重要价值,值得在临床进行推广应用。 Objective To study and explore diagnostic value of combined detection of tumor marker serum human epididymis secretory protein 4(HE4) and carbohydrate antigen 125(CA125) in ovarian cancer. Methods 100 patients with ovarian cancer who were admitted to our hospital from July 2013 to July 2015 were selected as the observation group and 100 healthy people were selected as the control group. Serum HE4 of 100 patients with ovarian cancer in the observation group and 100 healthy people in the control group were detected by enzyme linked immunoassay(ELISA). And CA125 level of them were detected by Electrochemiluminescence immunoassay(ECLIA). Detective statistics were received statistical analysis to explore diagnostic value of single or combined detection of two markers in ovarian cancer. Results Serum HE4 and CA 125 levels of the observation group were significantly improved when compared with those of the control group and the difference had statistical significance(P〈0.05). Diagnostic results of combined detection of serum HE4 and CA 125 showed that its sensitivity, specificity and accuracy were 88%, 93% and 91% respectively, all higher than those of single detection of HE4(81%, 82%, 73%) and CA125(83%, 81%, 83%). Conclusion Combined detection of serum HE4 and CA 125 has important significance diagnosis of ovarian cancer which can improve diagnosis efficiency of ovarian cancer. In addition, it has important value for early diagnosis, early diagnosis and early treatment of ovarian cancer, worthy of clinical promotion and application.
出处 《中国医药科学》 2015年第23期123-125,共3页 China Medicine And Pharmacy
关键词 卵巢癌 血清HE4 CA125 联合检测 诊断 价值 Ovarian cancer Serum HE4 CA125 Combined detection Diagnosis Value
  • 相关文献

参考文献16

二级参考文献145

  • 1李巍,崔恒,冯捷,李艺.卵巢癌诊断的研究进展[J].中华妇产科杂志,2005,40(7):496-498. 被引量:74
  • 2连利娟,林巧稚.妇科肿瘤学[M].第4版.北京:人民卫生出版社,2006:604.
  • 3乐杰.妇产科学[M].7版.北京:人民卫生出版社,2009:92-99.
  • 4Kirehhoff C, Habben I, Ive, II R ,et al. A major human epididymis - spe- cific cDNA encodes a protein with sequence homology to extracellular proteinase inhihitors[J]. Biol Repord,1991,45(2) :350 -357.
  • 5Moore RG, Brown AK, Miller MC et al. Utility of a novel serum tumorbiomarker HFA- in patients with endometrioid adenocarcinoma of the u- terus [ J ]. Gynecol Onco1,2008,110 ( 2 ) : 196 - 201.
  • 6Martina Montagnana, Giuseppe Lippi, Orazio Ruzzenente et al. The U- tility of serum human epididymis protein 4 ( HFA- ) in patients with a pelvic mass[ J ]. Journal of Clinical Laboratory Analysis ,2009,23 ( 5 ) : 331 -335.
  • 7Duffy M J, Bonfrer JM, Kulpa J,et al. CA 125 in ovarian cancer: Euro- pean Group on Tumour Markers guidelines for clinical use [ J ]. lnt J Gynecol Caneer,2005,15 (5) :679 - 691.
  • 8Ginath S, Menczer J, Fintsi Y,et al. Glezerman and 1. Avinoach,Tissue and serum CAI25 expression in endometrial cancer[ J ]. Int J Gynecol Cancer ,2002,12 (4) :372 - 375.
  • 9Nossov V ,Amneus M ,Su f,et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really sto better than ser- um CA - 125[J]. Am J Obstet Gynecol,2008,199(3) :215 -223.
  • 10He|lstrom 1, Raycraft J, Hayden - Ledbetter M, et al. The HFA ( WT -DC2 ) protein is a biomarker for ovarian carcinoma[ J ]. Cancer Res, 2003, 63(13) : 3695 -3700.

共引文献271

同被引文献98

  • 1谢幸,苟文丽.妇产科学[M].第8版.北京:人民卫生出版社,2013:258-264.
  • 2Oberaigner W,Minicozzi p,Bieiska-Lasota M,et al.Survival for ovarian Cancer in Europe:the across-country variation did not shrink in the past decade[J].Acta oncol,2012,51(4):441-453.
  • 3Anastasi E,Granato T,Coppa A,et al.HE4 in the differential diagnosis of a pelvic mass:a case report[J].Int JMol Sci,2011,12(1):627-632.
  • 4Hellstrom l,Raycraft J,Hayden-ledbetter M,et al.The HE4(Wfd C2)protein is abiomarker for ovarian carcinoma[J].Cancer Res,2003,63(3):695-700.
  • 5Moore Rg,Mc Meekin Ds,Brown Ak,et al.A novel multiple marker bioassay utillizing HE4 and CA125 for the prediction of ovarian cancer in patients with apelvic mass[J].Gynecol Oncol,2009,11(2):40-46.
  • 6Moore RG,Brown AK,Miller MC,et al.The use of multiple novel tumor biomarker for the detection of ovarian carcinoma in patients with a pelvic mass[J].Gynecol Oncol,2008,10(8):402-408.
  • 7Cristina A,Filomena MC,Elci IO,et al.A comparison of CA125,HE4,risk ovarian malignancy algorithm(ROMA)and risk malignancy index(RMI)for the classification of ovarian masses[J].Clinics,2012,67(5):437-441.
  • 8Karolina P,Bjorg KJ,Karin S,et al.Evaluation of ovarian cancer biomarkers HE4 and CA125 women presenting with a suspicios cystic ovarian masses[J].Gynecol Oncol,2012,22(4):244-252.
  • 9Wang TH,Chao A,Tsai CL,et al.Stress-induced phosphoprotein1 as a secretedbiomarker for human ovarian cancerpromotes cancer cell proliferation[J].Mol Cell Proteomics,2010,9(9):1873-1884.
  • 10Ferrar S,Braga F,Lanzoni M,et al.Serum humanepididymis protein 4 vs carbohydrate antigen 125 for ovariancancer diagnosis[J].Clin Pathol,2013,66(4):273-281.

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部